Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER
Close

Ionis Pharmaceuticals Inc (IONS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ionis Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
40.32 +0.12    +0.30%
02/12 - Closed. Currency in USD ( Disclaimer )
After Hours
39.93
-0.39
-0.97%
18:06:01 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,258,153
  • Bid/Ask: 39.93 / 40.54
  • Day's Range: 39.57 - 40.38
Ionis Pharma 40.32 +0.12 +0.30%

IONS Financial Summary

 
A brief financial summary of Ionis Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Ionis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 160 million compared to USD 133 million a year ago. Net loss was USD 47 million compared to USD 82 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.58 a year ago. Diluted loss per share from continuing operations was USD 0.33 compared to USD 0.58 a year ago.For the nine months, revenue was USD 435 million compared to USD 370 million a year ago. Net loss was USD 217 million compared to USD 253 million a year ago. Basic loss per share from continuing operations was USD 1.53 compared to USD 1.8 a year ago. Diluted loss per share from continuing operations was USD 1.53 compared to USD 1.8 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

IONS Income Statement

Gross margin TTM 18.46%
Operating margin TTM 2.36%
Net Profit margin TTM 0.84%
Return on Investment TTM 0.92%
 Total Revenue  Net Income
Period Ending: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021
Total Revenue 159.77 133.79 141.92
Gross Profit -24.74 -51.71 -23.38
Operating Income -59.15 -85.51 -57.5
Net Income -46.99 -105.14 -65.16

IONS Balance Sheet

Quick Ratio MRQ 7.04
Current Ratio MRQ 7.59
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 211.06%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021
Total Assets 2421.97 2456.13 2519.09 2611.69
Total Liabilities 1827.61 1831.41 1809.52 1839.95
Total Equity 594.36 624.73 709.57 771.74

IONS Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -8.62%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -24.43 -18.1 -31.65
Cash From Investing Activities -183.93 -3.3 -287.55
Cash From Financing Activities 1.83 1.22 -7.32
Net Change in Cash -206.92 -20.6 -326.68
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IONS Comments

Write your thoughts about Ionis Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Tullio Bressanello
Tullio Bressanello Oct 01, 2021 10:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What’s about this stock? Any new therapies are coming out?
Crim Jamer
Crim Jamer Oct 01, 2021 10:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
Bobo Müller
Bobo Müller Jun 09, 2021 12:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
Kurt Maxberry
Kurt Maxberry Jun 07, 2021 11:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Added 4000 at 34.4
Crim Jamer
Crim Jamer May 20, 2021 4:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice after market move!
Luke Sky
Luke Sky Apr 24, 2021 1:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
Crim Jamer
Crim Jamer Mar 22, 2021 5:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
Sean Landolt
Sean Landolt Sep 30, 2020 3:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this stock doesn't know what a green day looks like.
형진 조
형진 조 Sep 14, 2019 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ㅜㅜ~
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email